ELOCTATE 250

Riik: Iisrael

keel: inglise

Allikas: Ministry of Health

Toimeaine:

COAGULATION FACTOR VIII

Saadav alates:

SANOFI - AVENTIS ISRAEL LTD

ATC kood:

B02BD05

Ravimvorm:

POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

Koostis:

COAGULATION FACTOR VIII 250 IU

Manustamisviis:

I.V

Retsepti tüüp:

Required

Valmistatud:

BIOGEN IDEC LIMITED , UK

Terapeutiline ala:

COAGULATION FACTOR VII

Näidustused:

ELOCTATE [Antihemophilic Factor (Recombinant Fc Fusion Protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children12 years of age and older with Hemophilia A (congenital factor VIII deficiency) for:• Control and prevention of bleeding episodes.• Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.• Perioperative management (surgical prophylaxis).ELOCTATE is not indicated for the treatment of von Willebrand disease.

Loa andmise kuupäev:

2017-01-09